TSH receptor expression in orbital tissue and its role in the pathogenesis of Graves’ ophthalmopathy R. S. Bahn OriginalPaper 18 March 2014 Pages: 216 - 220
Eye muscle antibodies in Graves’ ophthalmopathy: Pathogenic or secondary epiphenomenon? T. MizokamiM. SalviJack R. Wall OriginalPaper 18 March 2014 Pages: 221 - 229
Role of thyroglobulin in the pathogenesis of Graves’ ophthalmopathy: The hypothesis of Kriss revisited Michelle MarinòL. ChiovatoA. Pinchera OriginalPaper 18 March 2014 Pages: 230 - 236
New understanding of the role of cytokines in the pathogenesis of Graves’ ophthalmopathy R. A. AjjanA. P. Weetman OriginalPaper 18 March 2014 Pages: 237 - 245
Novel aspects of orbital fibroblast pathology Terry J. Smith OriginalPaper 18 March 2014 Pages: 246 - 253
Recent developments in Graves’ ophthalmopathy imaging G. J. Kahaly OriginalPaper 18 March 2014 Pages: 254 - 258
Effects of Graves’ ophthalmopathy on quality of life W. M. WiersingaM. F. PrummelC. B. Terwee OriginalPaper 18 March 2014 Pages: 259 - 264
Relationship between cigarette smoking and Graves’ ophthalmopathy Laszlo HegedüsT. H. BrixP. Vestergaard OriginalPaper 18 March 2014 Pages: 265 - 271
Novel aspects of immunosuppressive and radiotherapy management of Graves’ ophthalmopathy Claudio MarcocciM. MarinòA. Pinchera OriginalPaper 18 March 2014 Pages: 272 - 280
Somatostatin analogs: A new tool for the management of Graves’ ophthalmopathy G. E. Krassas OriginalPaper 18 March 2014 Pages: 281 - 287
Relationship between management of hyperthyroidism and course of the ophthalmopathy L. BartalenaM. L. TandaA. Pinchera OriginalPaper 18 March 2014 Pages: 288 - 294
Graves’ ophthalmopathy: State of the art and perspectives Luigi BartalenaW. M. WiersingaA. Pinchera OriginalPaper 18 March 2014 Pages: 295 - 301
